SIC
VRTX icon

Sigma Investment Counselors’s Vertex Pharmaceuticals VRTX Stock Holding History

Sigma Investment Counselors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.51M Sell
9,089
-528
-5% -$234K 0.22% 68
2026
Q1 		$4.29M Sell
9,617
-404
-4% -$188K 0.23% 69
2025
Q4 		$4.54M Sell
10,021
-118
-1% -$50.9K 0.23% 72
2025
Q3 		$3.97M Buy
10,139
+840
+9% +$351K 0.21% 75
2025
Q2 		$4.14M Buy
9,299
+548
+6% +$253K 0.23% 71
2025
Q1 		$4.24M Sell
8,751
-251
-3% -$117K 0.26% 62
2024
Q4 		$3.63M Buy
9,002
+65
+0.7% +$30.1K 0.21% 71
2024
Q3 		$4.16M Buy
8,937
+260
+3% +$125K 0.24% 67
2024
Q2 		$4.07M Buy
8,677
+515
+6% +$224K 0.25% 68
2024
Q1 		$3.41M Buy
8,162
+910
+13% +$385K 0.22% 72
2023
Q4 		$2.95M Buy
7,252
+5,909
+440% +$2.18M 0.21% 70
2023
Q3 		$467K Buy
1,343
+74
+6% +$25.9K 0.04% 130
2023
Q2 		$447K Hold
1,269
– – 0.03% 132
2023
Q1 		$400K Hold
1,269
– – 0.03% 139
2022
Q4 		$366K Sell
1,269
-13
-1% -$3.96K 0.03% 141
2022
Q3 		$371K Sell
1,282
-9
-0.7% -$2.59K 0.03% 134
2022
Q2 		$364K Hold
1,291
– – 0.03% 137
2022
Q1 		$337K Sell
1,291
-826
-39% -$196K 0.02% 147
2021
Q4 		$465K Buy
2,117
+127
+6% +$24.7K 0.03% 135
2021
Q3 		$361K Buy
1,990
+148
+8% +$28.9K 0.03% 141
2021
Q2 		$371K Buy
1,842
+27
+1% +$5.65K 0.03% 139
2021
Q1 		$390K Buy
1,815
+266
+17% +$58.4K 0.03% 134
2020
Q4 		$366K Buy
+1,549
New +$355K 0.03% 135
2020
Q3 		– Sell
-980
Closed -$285K – 155
2020
Q2 		$285K Buy
+980
New +$266K 0.03% 129
2019
Q3 		– Sell
-1,177
Closed -$216K – 162
2019
Q2 		$216K Buy
1,177
+22
+2% +$3.85K 0.03% 150
2019
Q1 		$212K Buy
+1,155
New +$213K 0.03% 148
2018
Q4 		– Sell
-1,169
Closed -$225K – 154
2018
Q3 		$225K Buy
+1,169
New +$208K 0.03% 139

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sigma Investment Counselors's VRTX Position: Q2 2026 in Review

Sigma Investment Counselors reduced its Vertex Pharmaceuticals (VRTX) stake by 5.5% in Q2 2026, selling an estimated $234K and leaving 9,089 shares worth $4.51M. The position accounts for 0.22% of the portfolio, ranked #68.

Sigma Investment Counselors first reported a position in VRTX in Q3 2018 and has held it in 27 quarters since. The position peaked at $4.54M in Q4 2025. 1,764 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Sigma Investment Counselors held 9,089 shares of Vertex Pharmaceuticals worth $4.51M as of Q2 2026.
  • Sigma Investment Counselors sold 528 Vertex Pharmaceuticals shares in Q2 2026, an estimated $234K.
  • Vertex Pharmaceuticals made up 0.22% of Sigma Investment Counselors's portfolio in Q2 2026, its #68 holding.
  • Sigma Investment Counselors first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 27 quarters since.
  • Sigma Investment Counselors's Vertex Pharmaceuticals position peaked at $4.54M in Q4 2025.
  • 1,764 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sigma Investment Counselors's 13F filing for Q2 2026, filed 28 Jul 2026.